Mechanistically, Yap is Jak-dependently activated by interleukin (IL)-6, a key inflammatory cytokine in RA, and forms a complex with the transcription factor Snail to drive the SF invasive phenotype.

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

Preclinical models of Parkinson's disease (PD) have been developed using intracerebroventricular (i.c.v.) injection of 6-hydroxydopamine (6-OHDA) to induce neurodegeneration and motor dysfunction.

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

Revelation Biosciences (REVB) announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells exposed ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of ...

A recent clinical trial published in the BMC Nutrition journal examined the effects of melatonin supplementation on oxidative stress and inflammatory markers in diabetic patients with ...

Skin aging, an inevitable aspect of the aging process, has gained notable attention in research, particularly in the context of finding effective ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data ...

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) have received a consensus recommendation of “Buy” from the ...